Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.63 Average Price Target from Analysts

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $10.6250.

CRDF has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Wednesday, October 8th. HC Wainwright lowered their price target on shares of Cardiff Oncology from $18.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CRDF. The Manufacturers Life Insurance Company increased its position in Cardiff Oncology by 23.9% during the second quarter. The Manufacturers Life Insurance Company now owns 21,956 shares of the company’s stock worth $69,000 after purchasing an additional 4,232 shares during the last quarter. SteelPeak Wealth LLC grew its stake in shares of Cardiff Oncology by 23.2% during the 2nd quarter. SteelPeak Wealth LLC now owns 22,800 shares of the company’s stock valued at $72,000 after buying an additional 4,300 shares during the period. Invesco Ltd. increased its holdings in shares of Cardiff Oncology by 24.9% during the 2nd quarter. Invesco Ltd. now owns 23,795 shares of the company’s stock worth $75,000 after buying an additional 4,749 shares during the last quarter. Corebridge Financial Inc. raised its position in shares of Cardiff Oncology by 40.8% in the 1st quarter. Corebridge Financial Inc. now owns 28,555 shares of the company’s stock worth $90,000 after buying an additional 8,277 shares during the period. Finally, AlphaCore Capital LLC boosted its holdings in Cardiff Oncology by 8.2% in the third quarter. AlphaCore Capital LLC now owns 109,926 shares of the company’s stock valued at $226,000 after acquiring an additional 8,351 shares during the last quarter. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Price Performance

Cardiff Oncology stock opened at $2.08 on Friday. The stock has a market cap of $140.11 million, a PE ratio of -2.63 and a beta of 1.68. The stock’s fifty day moving average is $2.17 and its two-hundred day moving average is $2.74. Cardiff Oncology has a 1-year low of $1.90 and a 1-year high of $5.64.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.03. Cardiff Oncology had a negative net margin of 10,064.27% and a negative return on equity of 77.21%. The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.12 million. On average, research analysts expect that Cardiff Oncology will post -0.99 earnings per share for the current fiscal year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.